메뉴 건너뛰기




Volumn 14, Issue 3, 2013, Pages 321-336

Met, IGF1R, and other new targets in upper GI malignancies

Author keywords

Angiogenesis; Esophageal; Esophagogastric; Gastric; Hedgehog; HGF; IGF; MET, VEGF; Neuroendocrine; Pancreatic; Signaling; Trastuzumab

Indexed keywords

DIGESTIVE SYSTEM CANCER; GENE TARGETING; HUMAN; ONCOGENE; ONCOGENE IGF1R; ONCOGENE MET; REVIEW; UPPER GASTROINTESTINAL CANCER; UPPER GASTROINTESTINAL TRACT;

EID: 84884208894     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0245-5     Document Type: Review
Times cited : (2)

References (63)
  • 1
    • 84884207794 scopus 로고    scopus 로고
    • Accessed March 14, 2013
    • http://seer.cancer.gov/statfacts/html/pancreas.html; Accessed March 14, 2013.
  • 2
    • 84868017013 scopus 로고    scopus 로고
    • Burden of gastrointestinal disease in the United States: 2012 update
    • 22885331 10.1053/j.gastro.2012.08.002 e1-3
    • Peery AF et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179-87 e1-3.
    • (2012) Gastroenterology , vol.143 , pp. 1179-1187
    • Peery, A.F.1
  • 4
    • 0021241398 scopus 로고
    • Molecular cloning of a new transforming gene from a chemically transformed human cell line
    • 6590967 10.1038/311029a0 1:CAS:528:DyaL2cXmt1ersbk%3D
    • Cooper CS et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29.
    • (1984) Nature , vol.311 , pp. 29
    • Cooper, C.S.1
  • 5
    • 70149095573 scopus 로고    scopus 로고
    • Crosstalk between the VEGF-A and HGF signalling pathways in endothelial cells
    • 19281453 10.1042/BC20080221 1:CAS:528:DC%2BD1MXotVensbw%3D
    • Sulpice E et al. Crosstalk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell. 2009;101:525-39.
    • (2009) Biol Cell , vol.101 , pp. 525-539
    • Sulpice, E.1
  • 6
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • 1:CAS:528:DC%2BD2sXltlOjt7g%3D
    • Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Sci Signal. 2007;316:1039.
    • (2007) Sci Signal , vol.316 , pp. 1039
    • Engelman, J.A.1
  • 7
    • 33845713565 scopus 로고    scopus 로고
    • Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells
    • 17062641 10.1242/jcs.03236 1:CAS:528:DC%2BD2sXktF2k
    • Yamamoto N et al. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci. 2006;119:4623-33.
    • (2006) J Cell Sci , vol.119 , pp. 4623-4633
    • Yamamoto, N.1
  • 8
    • 80052511675 scopus 로고    scopus 로고
    • Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC
    • Spigel DR et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. ASCO Meet Abstr. 2011;29(15 Suppl):7505.
    • (2011) ASCO Meet Abstr , vol.29 , Issue.15 SUPPL. , pp. 7505
    • Spigel, D.R.1
  • 9
    • 56249137901 scopus 로고    scopus 로고
    • HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
    • 18974395 10.1158/1535-7163.MCT-08-0374 1:CAS:528:DC%2BD1cXhtlGgsrfK
    • Bachleitner-Hofmann T et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008;7:3499-508.
    • (2008) Mol Cancer Ther , vol.7 , pp. 3499-3508
    • Bachleitner-Hofmann, T.1
  • 10
    • 84881542709 scopus 로고    scopus 로고
    • The emerging role of MET/HGF inhibitors in oncology
    • doi: 10.1016/j.ctrv.2013.02.001.Excellent review article on molecular mechanisms in MET signaling
    • Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev. 2013. doi: 10.1016/j.ctrv.2013.02.001. Excellent review article on molecular mechanisms in MET signaling.
    • (2013) Cancer Treat Rev.
    • Scagliotti, G.V.1    Novello, S.2    Von Pawel, J.3
  • 11
    • 79955781270 scopus 로고    scopus 로고
    • Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells
    • 21252284 10.1158/1535-7163.MCT-10-0698 1:CAS:528:DC%2BC3MXivVCrsrg%3D
    • Liu L et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther. 2011;10:518-30.
    • (2011) Mol Cancer Ther , vol.10 , pp. 518-530
    • Liu, L.1
  • 12
    • 84865436737 scopus 로고    scopus 로고
    • Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
    • 22850551 10.1038/bjc.2012.335 1:STN:280:DC%2BC38fksFWksw%3D%3D
    • Minuti G et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 2012;107:793-9.
    • (2012) Br J Cancer , vol.107 , pp. 793-799
    • Minuti, G.1
  • 13
    • 84859377144 scopus 로고    scopus 로고
    • MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells
    • 10.1158/1535-7163.MCT-11-0754 22238368 10.1158/1535-7163.MCT-11-0754 1:CAS:528:DC%2BC38XjtlKisrs%3D [Epub Jan 11, 2012]
    • Chen CT et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther. 2012;11:660-9. doi: 10.1158/1535-7163.MCT-11-0754 [Epub Jan 11, 2012].
    • (2012) Mol Cancer Ther , vol.11 , pp. 660-669
    • Chen, C.T.1
  • 14
    • 84871556504 scopus 로고    scopus 로고
    • 6504 ORAL Safety and efficacy of epirubicin, cisplatin, and capecitabine (ecx) plus rilotumumab (r) as first-line treatment for unresectable locally advanced (la) or metastatic (m) gastric or esophagogastric junction (EGJ) adenocarcinoma
    • 10.1016/S0959-8049(11)71815-9
    • Iveson T et al. 6504 ORAL Safety and efficacy of epirubicin, cisplatin, and capecitabine (ecx) plus rilotumumab (r) as first-line treatment for unresectable locally advanced (la) or metastatic (m) gastric or esophagogastric junction (EGJ) adenocarcinoma. Eur J Cancer. 2011;47:S443.
    • (2011) Eur J Cancer , vol.47 , pp. 443
    • Iveson, T.1
  • 15
    • 77951494873 scopus 로고    scopus 로고
    • Targeted cancer therapies in the twenty-first century: Lessons from imatinib
    • 20237469 10.1038/clpt.2009.297 1:CAS:528:DC%2BC3cXkvFCntb8%3D
    • Stegmeier F et al. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010;87:543-52.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 543-552
    • Stegmeier, F.1
  • 16
    • 84870511276 scopus 로고    scopus 로고
    • Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer
    • Oliner K, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol. 2012;30.
    • (2012) J Clin Oncol. , pp. 30
    • Oliner, K.1
  • 17
    • 84875035582 scopus 로고    scopus 로고
    • Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in patients with metastatic gastric cancer
    • 23516391 10.1371/journal.pone.0054014 1:CAS:528:DC%2BC3sXltVSqtL8%3D
    • Shah MA et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8:e54014.
    • (2013) PLoS One , vol.8 , pp. 54014
    • Shah, M.A.1
  • 18
    • 79959897520 scopus 로고    scopus 로고
    • RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
    • 21543897 10.4161/cbt.12.1.15747 1:CAS:528:DC%2BC38XhtV2hsL4%3D
    • Catenacci DV et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011;12:9-46.
    • (2011) Cancer Biol Ther , vol.12 , pp. 9-46
    • Catenacci, D.V.1
  • 19
    • 84555190809 scopus 로고    scopus 로고
    • MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
    • 22042947 10.1200/JCO.2011.35.4928 1:CAS:528:DC%2BC38Xhslygs7w%3D
    • Lennerz JK et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803-10.
    • (2011) J Clin Oncol , vol.29 , pp. 4803-4810
    • Lennerz, J.K.1
  • 20
    • 84855398829 scopus 로고    scopus 로고
    • Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology
    • 22215692 10.1158/0008-5472.CAN-11-0550 1:CAS:528:DC%2BC38XhvVCktA%3D%3D Comprehensive review of complexities of IGF pathways
    • Gao J et al. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res. 2012;72:3-12. Comprehensive review of complexities of IGF pathways.
    • (2012) Cancer Res , vol.72 , pp. 3-12
    • Gao, J.1
  • 21
    • 66849140937 scopus 로고    scopus 로고
    • AMG 479, a fully human anti-insulin-like growth factor receptor type i monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
    • 19366899 10.1158/1535-7163.MCT-08-1171 1:CAS:528:DC%2BD1MXmtlGqsLY%3D
    • Beltran PJ et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009;8:1095-105.
    • (2009) Mol Cancer Ther , vol.8 , pp. 1095-1105
    • Beltran, P.J.1
  • 22
    • 0142231979 scopus 로고    scopus 로고
    • Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-X < sub > L protein expression during the progression of barrett's neoplasia
    • 14608530 10.1053/S0046-8177(03)00354-X 1:CAS:528:DC%2BD3sXot1GksbY%3D
    • Iravani S et al. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-X < sub > L protein expression during the progression of barrett's neoplasia. Hum Pathol. 2003;34:975-82.
    • (2003) Hum Pathol , vol.34 , pp. 975-982
    • Iravani, S.1
  • 23
    • 84875205826 scopus 로고    scopus 로고
    • Insulin/insulin-like growth Factor-1 pathway in Barrett's Carcinogenesis
    • 23466464 10.1038/ctg.2013.2 1:CAS:528:DC%2BC3sXhtFSru7fK
    • Greer KB et al. Insulin/insulin-like growth Factor-1 pathway in Barrett's Carcinogenesis. Clin Transl Gastroenterol. 2013;4:e31.
    • (2013) Clin Transl Gastroenterol , vol.4 , pp. 31
    • Greer, K.B.1
  • 24
    • 84862509365 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors
    • 22510349 10.1158/1078-0432.CCR-11-3369 1:CAS:528:DC%2BC38Xos1Oksrc%3D
    • Rosen LS et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2012;18:3414-27.
    • (2012) Clin Cancer Res , vol.18 , pp. 3414-3427
    • Rosen, L.S.1
  • 25
    • 84862531853 scopus 로고    scopus 로고
    • A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
    • 22700995 10.1093/annonc/mds142 1:STN:280:DC%2BC38jitVWhsQ%3D%3D
    • Kindler HL et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012;23:2834-42.
    • (2012) Ann Oncol , vol.23 , pp. 2834-2842
    • Kindler, H.L.1
  • 26
    • 84884207305 scopus 로고    scopus 로고
    • Updated analysis of phase ii study of the anti-IGF1R antibody MK-0646 with gemcitabine+/-erlotinib for advanced pancreatic cancer (APC)
    • 10.1093/annonc/mds151
    • Rachna S. Updated analysis of phase ii study of the anti-IGF1R antibody MK-0646 with gemcitabine+/-erlotinib for advanced pancreatic cancer (APC). Ann Oncol. 2012;23 Suppl 4:iv5-iv18.
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 4
    • Rachna, S.1
  • 27
    • 75749094341 scopus 로고    scopus 로고
    • Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma
    • 20150364 10.1093/neuonc/nop008 1:CAS:528:DC%2BC3cXjvFCntLo%3D
    • Yin S et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro-Oncology. 2010;12:19-27.
    • (2010) Neuro-Oncology , vol.12 , pp. 19-27
    • Yin, S.1
  • 28
    • 77956265929 scopus 로고    scopus 로고
    • IGF-1 receptor inhibition by picropodophyllin in medulloblastoma
    • 20692232 10.1016/j.bbrc.2010.08.009 1:CAS:528:DC%2BC3cXhtFamsb7J
    • Ohshima-Hosoyama S et al. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Biochem Biophys Res Commun. 2010;399:727-32.
    • (2010) Biochem Biophys Res Commun , vol.399 , pp. 727-732
    • Ohshima-Hosoyama, S.1
  • 29
    • 33646681444 scopus 로고    scopus 로고
    • HER2 and responsiveness of breast cancer to adjuvant chemotherapy
    • 16707747 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D
    • Pritchard KI et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103-11.
    • (2006) N Engl J Med , vol.354 , pp. 2103-2111
    • Pritchard, K.I.1
  • 30
    • 84859903908 scopus 로고    scopus 로고
    • Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes - A systematic review
    • 21780108 10.1002/ijc.26292 1:CAS:528:DC%2BC3MXhsVOkt7bE
    • Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes - a systematic review. Int J Cancer. 2012;130:2845-56.
    • (2012) Int J Cancer , vol.130 , pp. 2845-2856
    • Chua, T.C.1    Merrett, N.D.2
  • 31
    • 84867131579 scopus 로고    scopus 로고
    • Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis
    • 22689179 10.1093/annonc/mds104 1:STN:280:DC%2BC38jgvFSguw%3D%3D Important prospective analysis of HER2 expression in GI cancers
    • Janjigian YY et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656-62. Important prospective analysis of HER2 expression in GI cancers.
    • (2012) Ann Oncol , vol.23 , pp. 2656-2662
    • Janjigian, Y.Y.1
  • 32
    • 84880699219 scopus 로고    scopus 로고
    • Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
    • Shitara K, et al. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer. 2012;16:261-267.
    • (2012) Gastric Cancer. , vol.16 , pp. 261-267
    • Shitara, K.1
  • 33
    • 84877103264 scopus 로고    scopus 로고
    • Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
    • Okines AF, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2012;24(5):1253-1261.
    • (2012) Ann Oncol. , vol.24 , Issue.5 , pp. 1253-1261
    • Okines, A.F.1
  • 34
    • 84863409027 scopus 로고    scopus 로고
    • Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas
    • 22252257 10.1158/1078-0432.CCR-11-2272 1:CAS:528:DC%2BC38XhtVGqs7w%3D
    • Yoon HH et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012;18:546-54.
    • (2012) Clin Cancer Res , vol.18 , pp. 546-554
    • Yoon, H.H.1
  • 35
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial
    • 20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO First phase III study demonstrating efficacy of targeting HER2 in gastric cancer
    • Bang Y-J et al. Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687-97. First phase III study demonstrating efficacy of targeting HER2 in gastric cancer.
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.-J.1
  • 36
    • 84877605189 scopus 로고    scopus 로고
    • A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel vs weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study
    • Bang Y-J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel vs weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. ASCO Meeting Abstracts. 2013;31(4 Suppl):11.
    • (2013) ASCO Meeting Abstracts , vol.31 , Issue.4 SUPPL. , pp. 11
    • Bang, Y.-J.1
  • 37
    • 80054092983 scopus 로고    scopus 로고
    • Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2- positive cancer
    • 22003071 10.1158/1078-0432.CCR-11-0762 1:CAS:528:DC%2BC3MXhtlSksr3N
    • LoRusso PM et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2- positive cancer. Clin Cancer Res. 2011;17:6437-47.
    • (2011) Clin Cancer Res , vol.17 , pp. 6437-6447
    • Lorusso, P.M.1
  • 38
    • 84876011018 scopus 로고    scopus 로고
    • Phase II randomized study of trastuzumab emtansine vs trastuzumab plus docetaxel in patients with human epidermal growth factor Receptor 2- positive metastatic breast cancer
    • 23382472 10.1200/JCO.2012.44.9694 1:CAS:528:DC%2BC3sXntVyhtbs%3D
    • Hurvitz SA et al. Phase II randomized study of trastuzumab emtansine vs trastuzumab plus docetaxel in patients with human epidermal growth factor Receptor 2- positive metastatic breast cancer. J Clin Oncol. 2013;31:1157-63.
    • (2013) J Clin Oncol , vol.31 , pp. 1157-1163
    • Hurvitz, S.A.1
  • 39
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • 23020162 10.1056/NEJMoa1209124 1:CAS:528:DC%2BC38Xhs1ekt73M
    • Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.
    • (2012) N Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1
  • 40
    • 0346017700 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel
    • 14507946 10.1200/JCO.2003.12.109 1:CAS:528:DC%2BD2cXpsVajsb0%3D
    • Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel. J Clin Oncol. 2003;21:3965-71.
    • (2003) J Clin Oncol , vol.21 , pp. 3965-3971
    • Leyland-Jones, B.1
  • 41
    • 44249092320 scopus 로고    scopus 로고
    • Assessment of a HER2 scoring system for gastric cancer: Results from a validation study
    • 18422971 10.1111/j.1365-2559.2008.03028.x 1:STN:280: DC%2BD1czjtFWlsA%3D%3D
    • Hofmann M et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
    • (2008) Histopathology , vol.52 , pp. 797-805
    • Hofmann, M.1
  • 42
    • 34249933404 scopus 로고    scopus 로고
    • Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    • 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D
    • Moore MJ et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
    • (2007) J Clin Oncol , vol.25 , pp. 1960-1966
    • Moore, M.J.1
  • 43
    • 84884209694 scopus 로고    scopus 로고
    • Exploratory serum biomarker analyses from BO21129, a phase II study of erlotinib in second-line pancreatic cancer: Potential role of amphiregulin?
    • 10.1093/annonc/mds151
    • Ducreux M. Exploratory serum biomarker analyses from BO21129, a phase II study of erlotinib in second-line pancreatic cancer: potential role of amphiregulin? Ann Oncol. 2012;23 Suppl 4:iv5-iv18.
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 4
    • Ducreux, M.1
  • 44
    • 84868295867 scopus 로고    scopus 로고
    • A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3)
    • Waddell TS et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol. 2012;30(LBA4000):239.
    • (2012) J Clin Oncol , vol.30 , Issue.LBA4000 , pp. 239
    • Waddell, T.S.1
  • 45
    • 84875257151 scopus 로고    scopus 로고
    • Cetuximab in combination with capecitabine and cisplatin as first line treatment in advanced gastric cancer: Randomized controlled phase III EXPAND study
    • Lordick F et al. Cetuximab in combination with capecitabine and cisplatin as first line treatment in advanced gastric cancer: randomized controlled phase III EXPAND study. Ann Oncol. 2012;23:LBA3.
    • (2012) Ann Oncol , vol.23 , pp. 3
    • Lordick, F.1
  • 46
    • 70350780365 scopus 로고    scopus 로고
    • Structure and function of VEGF receptors
    • 19658168 10.1002/iub.234 1:CAS:528:DC%2BD1MXhtFSgtrfJ
    • Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61:915-22.
    • (2009) IUBMB Life , vol.61 , pp. 915-922
    • Stuttfeld, E.1    Ballmer-Hofer, K.2
  • 47
    • 33846629672 scopus 로고    scopus 로고
    • Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    • 17114652 10.1200/JCO.2006.08.0887 1:CAS:528:DC%2BD28XhtlemurbM
    • Shah MA et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201-6.
    • (2006) J Clin Oncol , vol.24 , pp. 5201-5206
    • Shah, M.A.1
  • 48
    • 77957160694 scopus 로고    scopus 로고
    • A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
    • 20332133 10.1093/annonc/mdq065 1:STN:280:DC%2BC3cfktFarsw%3D%3D
    • El-Rayes BF et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21:1999-2004.
    • (2010) Ann Oncol , vol.21 , pp. 1999-2004
    • El-Rayes, B.F.1
  • 49
    • 80053573446 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
    • 21844504 10.1200/JCO.2011.36.2236 1:CAS:528:DC%2BC3MXhsFams7bM
    • Ohtsu A et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968-76.
    • (2011) J Clin Oncol , vol.29 , pp. 3968-3976
    • Ohtsu, A.1
  • 50
    • 84863897798 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial
    • 22565005 10.1200/JCO.2011.39.9824
    • Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119-27.
    • (2012) J Clin Oncol , vol.30 , pp. 2119-2127
    • Van Cutsem, E.1
  • 51
    • 84878078429 scopus 로고    scopus 로고
    • REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) vs placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
    • Fuchs CS et al. REGARD: a phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) vs placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. ASCO Meet Abstr. 2013;31(4 Suppl):LBA5.
    • (2013) ASCO Meet Abstr , vol.31 , Issue.4 SUPPL. , pp. 5
    • Fuchs, C.S.1
  • 52
    • 52149119128 scopus 로고    scopus 로고
    • A paracrine requirement for hedgehog signalling in cancer
    • 18754008 10.1038/nature07275 1:CAS:528:DC%2BD1cXhtFams7fP
    • Yauch RL et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406-10.
    • (2008) Nature , vol.455 , pp. 406-410
    • Yauch, R.L.1
  • 53
    • 84887565114 scopus 로고    scopus 로고
    • A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study
    • Cohen DJ et al. A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led study. ASCO Meeting Abstracts. 2013;31(4 Suppl):67.
    • (2013) ASCO Meeting Abstracts , vol.31 , Issue.4 SUPPL. , pp. 67
    • Cohen, D.J.1
  • 54
    • 84885858421 scopus 로고    scopus 로고
    • Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update
    • Sekulic A et al. Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. ASCO Meet Abstr. 2012;30(15 Suppl):8579.
    • (2012) ASCO Meet Abstr , vol.30 , Issue.15 SUPPL. , pp. 8579
    • Sekulic, A.1
  • 55
    • 80053317491 scopus 로고    scopus 로고
    • Basal cell carcinoma: From the molecular understanding of the pathogenesis to targeted therapy of progressive disease
    • Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2010;2011.
    • J Skin Cancer.; 2010 , vol.2011
    • Göppner Leverkus D, M.1
  • 56
    • 33745745896 scopus 로고    scopus 로고
    • Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer
    • 16831586 10.1053/j.gastro.2006.05.008 1:CAS:528:DC%2BD28XnvF2gsL4%3D
    • Fukaya M et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology. 2006;131:14-29.
    • (2006) Gastroenterology , vol.131 , pp. 14-29
    • Fukaya, M.1
  • 57
    • 79960340656 scopus 로고    scopus 로고
    • Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor
    • 21430703 10.1038/jid.2011.48 1:CAS:528:DC%2BC3MXovFarsr8%3D
    • Skvara H et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131:1735-44.
    • (2011) J Invest Dermatol , vol.131 , pp. 1735-1744
    • Skvara, H.1
  • 58
    • 84868107516 scopus 로고    scopus 로고
    • BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
    • 22771827 10.1093/annonc/mds135 1:STN:280:DC%2BC38jotFWrtQ%3D%3D
    • Goncalves A et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012;23:2799-805.
    • (2012) Ann Oncol , vol.23 , pp. 2799-2805
    • Goncalves, A.1
  • 59
    • 79851500081 scopus 로고    scopus 로고
    • Everolimus for advanced pancreatic neuroendocrine tumors
    • 21306238 10.1056/NEJMoa1009290 1:CAS:528:DC%2BC3MXhvVyiu7s%3D First study to demonstrate survival advantage of any therapy in unresectable neuroendocrine carcinoma
    • Yao JC et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23. First study to demonstrate survival advantage of any therapy in unresectable neuroendocrine carcinoma.
    • (2011) N Engl J Med , vol.364 , pp. 514-523
    • Yao, J.C.1
  • 60
    • 84884211163 scopus 로고    scopus 로고
    • Systemic therapy for metastatic renal cell carcinoma: A review and update
    • 23526579
    • Logan JE et al. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012;14:65.
    • (2012) Rev Urol , vol.14 , pp. 65
    • Logan, J.E.1
  • 61
    • 84874862127 scopus 로고    scopus 로고
    • Everolimus in advanced pancreatic neuroendocrine tumors: The clinical experience
    • 23436795 10.1158/0008-5472.CAN-12-3923 1:CAS:528:DC%2BC3sXjtlGqtb0%3D
    • Yao JC et al. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013;73:1449-53.
    • (2013) Cancer Res , vol.73 , pp. 1449-1453
    • Yao, J.C.1
  • 62
    • 84861392332 scopus 로고    scopus 로고
    • Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1
    • Van Cutsem E et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol. 2012;30 Suppl 4:LBA3.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 4 , pp. 3
    • Van Cutsem, E.1
  • 63
    • 84255162255 scopus 로고    scopus 로고
    • Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis
    • 21964956 10.1002/lt.22441
    • Liang W et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:62-9.
    • (2012) Liver Transpl , vol.18 , pp. 62-69
    • Liang, W.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.